This study, called SAVAL, is looking at a new way to decide who needs radiation after surgery for HPV-related oropharyngeal (throat) cancer. People with this type of cancer often do well, but treatments can have significant side effects. The study wants to see if a blood test called a Circulating Tumor DNA test (ctDNA test) can help reduce the number of people who need radiation. You might be able to join if you are 18 or older and have a confirmed diagnosis of p16+ squamous cell carcinoma of the oropharynx. The main goal is to see how long people live without their cancer progressing (Progression-free Survival) after two years. The current status of the study is unclear, and it plans to enroll 61 people.

Study design

This is an interventional study planning to enroll 61 participants. It involves different groups: some will be observed, and others will receive standard radiation treatment.

What's involved

You will undergo a ctDNA blood test before and after surgery, and then every three months for two years after treatment.

Compensation

Not stated in the trial record.

Follow-up

Your progression-free survival will be measured for two years after your last treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.